Breaking News Instant updates and real-time market news.

MRNS

Marinus Pharmaceuticals

$5.18

-0.12 (-2.26%)

07:52
12/10/18
12/10
07:52
12/10/18
07:52

Marinus Pharmaceuticals announces results from two ganaxolone studies

Marinus Pharmaceuticals announced "positive" results from its Phase 2 clinical trials evaluating ganaxolone intravenous, or IV, and oral in women with postpartum depression, or PPD. Based on these results, the company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens. There was a clear dose response relationship seen for three groups of patients receiving ganaxolone IV at median doses of 60, 90 and 140 microg/kg/h.The 140 microg/kg/h dose group demonstrated the most robust results, with a clinically meaningful 5.6-point reduction in Hamilton Rating Scale for Depression, or HAM-D17, compared to placebo at 48 hours that was durable through the last visit, day 34. These patients had a mean HAM-D17 reduction of 16.9 and 15.7 points from baseline at 60 hours and day 34, respectively. Overall, 75% of patients were responders, as defined as having a 50% reduction from baseline, at day 34 and 67% were responders at 60 hours. Additionally, 50% of patients achieved remission from depression, as determined by a HAM-D17 of 7, at day 34 and 33% achieved remission at 60 hours. Ganaxolone was safe and well-tolerated in all dose groups. Consistent with previous ganaxolone studies, the most common reported adverse events were sedation and dizziness. There were no serious adverse events reported, no discontinuations due to a treatment related adverse event and consistent with prior studies, there were no reports of syncope or loss of consciousness. The Clinical Global Impression of Improvement, or CGI-I, as well as the Edinburgh Postnatal Depression Survey, or EPDS, and Spielberger State-Trait Anxiety 6, or STAI-6, showed highly similar trends that were consistent with HAM-D17. Overall, 58 patients with PPD were randomized on a 1:1 basis to receive one of three ascending fixed IV 60-hour dose regimens of ganaxolone or placebo. No initial up titration was required and patients were down titrated over the final 12 hours of the 60-hour infusion. A bolus injection of ganaxolone prior to the 60-hour infusion was explored to test the safety and tolerability of a very short, high dose infusion. None of the dose groups were powered to generate statistical significance. Patients with a HAM-D17 score of 26 were considered for enrollment in the study. HAM-D17 measurements were conducted by a centralized rater and taken at various timepoints spanning from baseline to day 34. Enrollment is ongoing in the company's oral study, a Phase 2 clinical trial to evaluate the safety, tolerability and efficacy of oral ganaxolone in women with PPD. Patients with a HAM-D17 score of 20 but less than 26 are being considered for enrollment in the study. Cohorts of patients enrolled in the initial open label phase of the study receive ascending dose regimens with oral ganaxolone. The efficacy endpoint is change from baseline in the HAM-D17 score. Patients in the most recent dose cohort who took oral ganaxolone for four weeks had a mean HAM-D17 reduction of 13.2 points 28 days from a baseline of 24.7 and a reduction of 15.7 points at day 36. This cohort is on-going and not all patients have reached day 28. As with IV, oral ganaxolone was generally safe and well-tolerated with no serious adverse events reported and no discontinuations due to treatment related adverse events. The company is advancing both the Magnolia and Amaryllis studies with data expected in the first half of 2019. The second part of the Magnolia Study will evaluate a short IV infusion followed by oral ganaxolone administration and the Amaryllis study will continue to optimize oral ganaxolone dosing.

MRNS Marinus Pharmaceuticals
$5.18

-0.12 (-2.26%)

07/19/18
MZHO
07/19/18
NO CHANGE
Target $13
MZHO
Buy
Marinus can rally 100% on postpartum depression data, says Mizuho
Mizuho analyst Difei Yang believes Marinus Pharmaceuticals' Q3 top-line data from part 1 of the Phase 2 Magnolia study of ganaxolone IV in women with postpartum depression will be an "important catalyst" for the shares. The analyst sees upside potential of 100%-plus, assuming "convincing data including a clear dose response." She believes the downside is limited given the history of the compound and potential in other indications. Yang reiterates a Buy rating on Marinus with a $13 price target.
07/02/18
CANT
07/02/18
INITIATION
Target $19
CANT
Overweight
Marinus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros started Marinus Pharmaceuticals with an Overweight rating and $19 price target. The analyst views the stock's risk/reward as compelling into upcoming data catalysts for ganaxolone, a positive allosteric modulator of GABAA receptor.
06/06/18
LTCO
06/06/18
INITIATION
Target $20
LTCO
Buy
Marinus Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Michael Higgins started Marinus Pharmaceuticals with a Buy rating and $20 price target.
05/24/18
05/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) initiated with an Outperform at Evercore ISI. 2. Caesars (CZR) initiated with an Overweight at JPMorgan. 3. e.l.f. Beauty (ELF) initiated with an Outperform at Oppenheimer. 4. uniQure (QURE) initiated with a Buy at SunTrust. 5. Marinus Pharmaceuticals (MRNS) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

03:45
12/10/19
12/10
03:45
12/10/19
03:45
General news
FX Action: USD-CAD has consolidated below 1.3250 »

FX Action: USD-CAD has…

03:00
12/10/19
12/10
03:00
12/10/19
03:00
General news
FX Update: The New Zealand dollar posted a fresh four-month high »

FX Update: The New…

02:00
12/10/19
12/10
02:00
12/10/19
02:00
General news
U.S. productivity preview: »

U.S. productivity…

01:45
12/10/19
12/10
01:45
12/10/19
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

21:55
12/09/19
12/09
21:55
12/09/19
21:55
General news
Treasury Market Summary »

Treasury Market Summary:…

AUPH

Aurinia Pharmaceuticals

$15.76

0.31 (2.01%)

21:03
12/09/19
12/09
21:03
12/09/19
21:03
Syndicate
Aurinia Pharmaceuticals 11.1M share Secondary priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

20:08
12/09/19
12/09
20:08
12/09/19
20:08
Downgrade
Gardner Denver rating change at BTIG »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

19:56
12/09/19
12/09
19:56
12/09/19
19:56
Downgrade
Gardner Denver rating change at BTIG »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTCWY

Deutsche Wohnen

$0.00

(0.00%)

19:50
12/09/19
12/09
19:50
12/09/19
19:50
Downgrade
Deutsche Wohnen rating change at Goldman Sachs »

Deutsche Wohnen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEGXF

Segro

$0.00

(0.00%)

19:49
12/09/19
12/09
19:49
12/09/19
19:49
Downgrade
Segro rating change at Goldman Sachs »

Segro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BORR

Borr Drilling

$6.60

0.46 (7.49%)

19:30
12/09/19
12/09
19:30
12/09/19
19:30
Initiation
Borr Drilling initiated at Goldman Sachs »

Borr Drilling initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$6.89

-0.05 (-0.72%)

19:26
12/09/19
12/09
19:26
12/09/19
19:26
Syndicate
Breaking Syndicate news story on Inseego »

Inseego files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$30.44

16.04 (111.39%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ARQL

ArQule

$19.71

10.035 (103.77%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
ArQule »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

XNCR

Xencor

$41.41

0.39 (0.95%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ABR

Arbor Realty

$14.78

(0.00%)

19:20
12/09/19
12/09
19:20
12/09/19
19:20
Syndicate
Arbor Realty 6.5M share Spot Secondary priced at $14.14 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

STRM

Streamline Health

$1.25

-0.04 (-3.10%)

18:59
12/09/19
12/09
18:59
12/09/19
18:59
Hot Stocks
Streamline Health delaying Q3 results to resolve amortization charge »

Streamline Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

, INTC

Intel

$56.52

-0.28 (-0.49%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Periodicals
McAfee weighs combination with NortonLifeLock, WSJ reports »

NortonLifeLock (NLOK) has…

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

INTC

Intel

$56.52

-0.28 (-0.49%)

AVGO

Broadcom

$314.49

-1.68 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 19

    Dec

  • 23

    Jan

TGTX

TG Therapeutics

$9.28

2.17 (30.52%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Conference/Events
TG Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

NTNX

Nutanix

$33.87

-0.725 (-2.10%)

18:41
12/09/19
12/09
18:41
12/09/19
18:41
Hot Stocks
Nutanix CEO: We are transitioning to a subscription-based model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

  • 16

    Dec

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

, MDB

MongoDB

$131.03

-0.19 (-0.14%)

18:33
12/09/19
12/09
18:33
12/09/19
18:33
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Stitch…

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

MDB

MongoDB

$131.03

-0.19 (-0.14%)

PHR

Phreesia

$29.01

-0.09 (-0.31%)

CDMO

Avid Bioservices

$5.85

0.05 (0.86%)

MTN

Vail Resorts

$231.30

-1.43 (-0.61%)

TOL

Toll Brothers

$41.40

0.515 (1.26%)

EQ

Equillium

$4.00

-0.03 (-0.74%)

SUPN

Supernus

$22.69

-0.145 (-0.63%)

A

Agilent

$81.68

-0.545 (-0.66%)

HEPA

Hepion Pharmaceuticals

$5.61

0.4 (7.68%)

ROAD

Construction Partners

$20.56

0.66 (3.32%)

CASY

Casey's General Stores

$175.33

-0.47 (-0.27%)

CHWY

Chewy

$24.17

-0.76 (-3.05%)

LVGO

Livongo Health

$27.40

-0.6 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 18

    Dec

  • 19

    Dec

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

, BMY

Bristol-Myers

$61.32

1.38 (2.30%)

18:24
12/09/19
12/09
18:24
12/09/19
18:24
Hot Stocks
Bluebird Bio, Bristol-Myers present update on Phase 1 study of bb21217 »

Bluebird bio (BLUE) and…

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

BMY

Bristol-Myers

$61.32

1.38 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

BA

Boeing

$351.25

-2.74 (-0.77%)

18:22
12/09/19
12/09
18:22
12/09/19
18:22
Periodicals
Former Boeing employee Pierson to testify at U.S. House hearing, Reuters says »

An ex-Boeing employee who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:21
12/09/19
12/09
18:21
12/09/19
18:21
Hot Stocks
Occidental Petroleum director buys 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:14
12/09/19
12/09
18:14
12/09/19
18:14
Hot Stocks
Occidental Petroleum director buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.